BioSyent Named to the PROFIT 500 Ranking of Canada's Fastest-Growing Companies with a 5 year Revenue Growth Rate of 608%

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that Canadian
Business and PROFIT has ranked BioSyent as one of Canada's Fastest-Growing
Companies in the just released 2014 rankings. Published in the July issue of
Canadian Business and online at PROFITguide.com, the PROFIT 500 ranks Canadian
businesses by their revenue growth over five years. Based upon a five year
revenue (2008-2013) growth rate of 608%, BioSyent ranked 104 on the PROFIT 500
list. This is the second consecutive year that BioSyent has been named to the
Profit 500 list and marks a significant increase in 5 year growth rate, from
355% on last year's list to 608% on this year's list.


For a direct market quote (15 minutes delay) for the TSX Venture Exchange and
other Company financial information please visit www.tmxmoney.com.


About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent
is a profitable growth oriented specialty pharmaceutical company which searches
the globe to in-license or acquire innovative pharmaceutical products that have
been successfully developed, are safe and effective, and have a proven track
record of improving the lives of patients and supporting the healthcare
professionals that treat them.


Once a product of interest has been found, BioSyent then acquires the exclusive
rights to the product and manages it through the Canadian governmental
regulatory approval process. Once approved, BioSyent markets the product
throughout Canada.


At the date of this press release the Company had 13,801,195 shares issued and
outstanding.


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.


The TSX Venture Exchange assumes no responsibility for the accuracy of this
release and neither approves nor disapproves of the same.


FOR FURTHER INFORMATION PLEASE CONTACT: 
BioSyent Inc.
Mr. Rene C. Goehrum
President and CEO
[phone]
[e-mail]
www.biosyent.com